Protagonist Therapeutics

Stories

FDA approves Mimrylo, first-of-its-kind drug for polycythemia vera

As of September 2026: Receiving $275M in payments tied to the FDA approval

Polycythemia vera has been treated with bloodletting for more than a century. On August 28, the FDA approved Mimrylo (rusfertide), the first drug mimicking hepcidin, the hormone that limits iron for red blood cell production.

Updated Sep 1

First oral biologic for psoriasis reaches patients, opening new front in autoimmune treatment

New Capabilities

As of May 2026: Originator of icotrokinra; earning milestones and royalties

For two decades, treating moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions many patients refused or abandoned. On March 18, 2026, the FDA approved ICOTYDE, a once-daily pill that blocks the IL-23 receptor like injectable biologics. In trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of placebo.

Updated May 30